Adverse events | HPP/target-therapy, N = 27 | HAI/target therapy, N = 9 | Total, N = 36 | |
---|---|---|---|---|
Grade | N (%) | N (%) | N (%) | |
Bone marrow hypocellurarity | −1/2 | 3 (11) | 1 (11) | 4 (11) |
−3/4 | 1 (4) | 0 | 1 (3) | |
Nausea/vomiting | −1/2 | 3 (11) | 1 (11) | 4 (11) |
−3/4 | 0 | 1 (11) | 1 (3) | |
Diarrhea | −1/2 | 0 | 1 (11) | 1 (3) |
−3/4 | 0 | 0 | 0 | |
Alopecia | −1/2 | 2 (7) | 1 (11) | 3 (8) |
−3/4 | 0 | 0 | 0 | |
Fatigue | −1/2 | 2 (7) | 1 (11) | 3 (8) |
−3/4 | 0 | 0 | 0 | |
Neuropaty | −1/2 | 2 (7) | 1 (11) | 3 (8) |
−3/4 | 0 | 0 | 0 | |
Hand Foot Syndrome | −1/2 | 0 | 1 (11) | 1 (3) |
−3/4 | 0 | 0 | 0 | |
Rash | −1/2 | 0 | 2 (22) | 2 (5.5) |
−3/4 | 0 | 0 | 0 | |
Non-infectious fever | −1/2 | 0 | 4 (44) | 4 (11) |
−3/4 | 0 | 0 | 0 | |
Perineal skin toxicity | −1/2 | 6 (22) | 0 | 6 (16.6) |
−3/4 | 5 (18) | 0 | 5 (14) | |
AST and ALT increased | −1/2 | 0 | 1 (11) | 1 (3) |
−3/4 | 0 | 0 | 0 | |
Persistent leakage of fluid from the inguinal incision | −1/2 | 3 (11) | 0 | 3 (8) |
−3/4 | 1 (4) | 0 | 1 (3) | |
Inguinal hematoma | -1/2 | 1 (4) | 1 (11) | 2 (5.5) |
-3/4 | 0 | 0 | 0 |